HomeNewsBusinessMarketsHUL to underperform in short term given expensive valuations: Ashish Chaturmohta

HUL to underperform in short term given expensive valuations: Ashish Chaturmohta

In the medium term, HUL should farewell as it will be a key beneficiary of the rural demand recovery and one of the least impacted companies from COVID-19 led disruptions.

May 04, 2020 / 11:50 IST
Story continues below Advertisement

HUL is expected to underperform given the expensive valuations and poor quarterly performance, but, in the medium term, HUL could do well as it will be a key beneficiary of the rural demand recovery and one of the least impacted companies from COVID-19 led disruptions, Ashish Chaturmohta, Head of Technical and Derivatives, Sanctum Wealth Management., said in an interview with Moneycontrol’s Kshitij Anand.

Story continues below Advertisement

edited excerpts:

Q) What is fuelling market rally on D-Street?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show